Treatment with the therapy, which is a combination of two monoclonal antibodies -- Casirivimab and Imdevimab -- was touted as a game changer with its better hold on the deadly Covid pandemic by Indian hospitals. It has also received an emergency use authorisation (EUA) in India by the Central Drugs Standards Control Organisation (CDSCO) in May.